DexCom DXCM releases its next round of earnings this Wednesday, May 1. Get the latest predictions in Benzinga's essential guide to the company's first-quarter earnings report.
Earnings and Revenue
Wall Street analysts see DexCom reporting a quarterly loss of 16 cents per share on sales of $246.39 million.
In the same quarter last year, DexCom reported an EPS loss of 32 cents on revenue of $184.4 million. Sales would be up 33.62 percent from the same quarter last year. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | 0.17 | -0.1 | -0.18 | -0.33 | 0.03 |
| EPS Actual | 0.54 | 0.17 | -0.1 | -0.32 | 0.1 |
Stock Performance
Over the last 52-week period, shares are up 65.44 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. The most common rating from analysts on DexCom stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
DexCom's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: https://www.dexcom.com/en-IN
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
